PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
GSK vs. MAIN
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Key characteristics


GSKMAIN
YTD Return18.11%18.65%
1Y Return22.43%34.68%
3Y Return (Ann)8.78%13.96%
5Y Return (Ann)5.67%12.81%
10Y Return (Ann)2.50%13.26%
Sharpe Ratio1.332.83
Daily Std Dev18.07%12.58%
Max Drawdown-55.72%-64.53%
Current Drawdown-1.78%-0.52%

Fundamentals


GSKMAIN
Market Cap$83.99B$4.18B
EPS$2.99$5.23
PE Ratio13.759.39
PEG Ratio1.092.09
Revenue (TTM)$30.33B$500.38M
Gross Profit (TTM)$19.92B$376.86M

Correlation

-0.50.00.51.00.2

The correlation between GSK and MAIN is 0.23, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Performance

GSK vs. MAIN - Performance Comparison

The year-to-date returns for both investments are quite close, with GSK having a 18.11% return and MAIN slightly higher at 18.65%. Over the past 10 years, GSK has underperformed MAIN with an annualized return of 2.50%, while MAIN has yielded a comparatively higher 13.26% annualized return. The chart below displays the growth of a $10,000 investment in both assets, with all prices adjusted for splits and dividends.


0.00%200.00%400.00%600.00%800.00%1,000.00%1,200.00%December2024FebruaryMarchAprilMay
82.34%
1,251.96%
GSK
MAIN

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


GlaxoSmithKline plc

Main Street Capital Corporation

Risk-Adjusted Performance

GSK vs. MAIN - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for GlaxoSmithKline plc (GSK) and Main Street Capital Corporation (MAIN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


GSK
Sharpe ratio
The chart of Sharpe ratio for GSK, currently valued at 1.33, compared to the broader market-2.00-1.000.001.002.003.004.001.33
Sortino ratio
The chart of Sortino ratio for GSK, currently valued at 2.05, compared to the broader market-4.00-2.000.002.004.006.002.05
Omega ratio
The chart of Omega ratio for GSK, currently valued at 1.24, compared to the broader market0.501.001.501.24
Calmar ratio
The chart of Calmar ratio for GSK, currently valued at 0.92, compared to the broader market0.002.004.006.000.92
Martin ratio
The chart of Martin ratio for GSK, currently valued at 5.38, compared to the broader market-10.000.0010.0020.0030.005.38
MAIN
Sharpe ratio
The chart of Sharpe ratio for MAIN, currently valued at 2.83, compared to the broader market-2.00-1.000.001.002.003.004.002.83
Sortino ratio
The chart of Sortino ratio for MAIN, currently valued at 3.94, compared to the broader market-4.00-2.000.002.004.006.003.94
Omega ratio
The chart of Omega ratio for MAIN, currently valued at 1.50, compared to the broader market0.501.001.501.50
Calmar ratio
The chart of Calmar ratio for MAIN, currently valued at 3.73, compared to the broader market0.002.004.006.003.73
Martin ratio
The chart of Martin ratio for MAIN, currently valued at 11.56, compared to the broader market-10.000.0010.0020.0030.0011.56

GSK vs. MAIN - Sharpe Ratio Comparison

The current GSK Sharpe Ratio is 1.33, which is lower than the MAIN Sharpe Ratio of 2.83. The chart below compares the 12-month rolling Sharpe Ratio of GSK and MAIN.


Rolling 12-month Sharpe Ratio-0.500.000.501.001.502.002.503.00December2024FebruaryMarchAprilMay
1.33
2.83
GSK
MAIN

Dividends

GSK vs. MAIN - Dividend Comparison

GSK's dividend yield for the trailing twelve months is around 3.35%, less than MAIN's 7.78% yield.


TTM20232022202120202019201820172016201520142013
GSK
GlaxoSmithKline plc
3.35%3.75%4.72%4.93%5.53%4.35%5.53%5.80%6.89%5.94%6.18%4.49%
MAIN
Main Street Capital Corporation
7.78%8.55%7.97%5.74%6.99%6.76%8.43%7.02%7.42%9.15%8.72%8.18%

Drawdowns

GSK vs. MAIN - Drawdown Comparison

The maximum GSK drawdown since its inception was -55.72%, smaller than the maximum MAIN drawdown of -64.53%. Use the drawdown chart below to compare losses from any high point for GSK and MAIN. For additional features, visit the drawdowns tool.


-25.00%-20.00%-15.00%-10.00%-5.00%0.00%December2024FebruaryMarchAprilMay
-1.78%
-0.52%
GSK
MAIN

Volatility

GSK vs. MAIN - Volatility Comparison

GlaxoSmithKline plc (GSK) has a higher volatility of 5.49% compared to Main Street Capital Corporation (MAIN) at 3.44%. This indicates that GSK's price experiences larger fluctuations and is considered to be riskier than MAIN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


2.00%3.00%4.00%5.00%6.00%7.00%December2024FebruaryMarchAprilMay
5.49%
3.44%
GSK
MAIN

Financials

GSK vs. MAIN - Financials Comparison

This section allows you to compare key financial metrics between GlaxoSmithKline plc and Main Street Capital Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities



Values in USD except per share items